Viral hepatitis – Related resources

Cochrane reviews

• Ribavirin alone appears to have no significant beneficial effect on virological response and liver morbidity in chronic hepatitis C as compared to placebo or no intervention, but may improve biochemical and histological response transiently .

• Because of poor quality of available studies, there is insufficient evidence on the effectiveness of hepatitis B vaccination on the risk of hepatitis B in children or grown-ups who have not been previously exposed to hepatitis B infection or whose exposure status is not known. According to analysis restricted to participants available for follow-up, vaccination seems to be effective .
• Antiviral therapy for recurrent liver graft infection with hepatitis C virus seems to lack clinical benefit, but there is insufficient evidence from adequate trials .
• Among patients with stable HIV, the treatment of concomitant chronic hepatitis C with peginterferon plus ribavirin may be more effective than interferon plus ribavirin or peginterferon alone in achieving a virological response .

Literature

• Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ 2010 Jan 5;340():b5429.
• Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010 Feb;52(2):176-82.
• Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010 Jan;138(1):108-15.
• Nash KL, Bentley I, Hirschfield GM. Managing hepatitis C virus infection. BMJ 2009 Jun 26;338():b2366.
• Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008 Oct 2;359(14):1486-500.
• Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008 Jul 26;372(9635):321-32.
• Hadziyannis SJ, Sette H Jr, Morgan TR et al; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 Mar 2;140(5):346-55.
• Dalgard O, Bjøro K, Ring-Larsen H et al; North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008 Jan;47(1):35-42.
• von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 Aug;129(2):522-7.
• Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 Jun 23;352(25):2609-17.
• Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006 Jan;44(1):97-103.
• Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 May;43(5):954-60.
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009 Sep;50(3):661-2.